Copyright © 2009 KDIGO. All rights reserved. Do not distribute without permission.

KDIGO Controversies Conference
Chronic Kidney Disease: Definition, Classification, and Prognosis

4-6 October, 2009
London, England

CONFERENCE LEADERS

PLANNING COMMITTEE:

Andrew Levey, MD - Conf. Chair
Tufts Medical Center
Boston, USA
alevey@tufts-nemc.org

Meguid El Nahas, MD - Conf. Co-Chair
University of Sheffield
Sheffield, UK
m.el-nahas@sheffield.ac.uk

Bertram Kasiske, MD – KDIGO Co-Chair
Hennepin County Medical Center
Minneapolis, USA
kasis001@um.edu

Paul de Jong, MD – Conf. Co-Chair
University Hospital Groningen
Groningen, The Netherlands
p.e.de.jong@int.azg.nl

Josef Coresh, MD – Conf. Co-Chair
Johns Hopkins University
Baltimore, USA
coresh@jhu.edu

Kai-Uwe Eckardt, MD – KDIGO Co-Chair
University Hospital Erlangen
Erlangen, Germany
Kai-Uwe.Eckardt@uk-erlangen.de

ANALYTICAL TEAM:

Brad Astor, PhD
Johns Hopkins University
Baltimore, USA
bastor@jhsph.edu

Ron Gansevoort, MD, PhD
University Hospital Groningen
Groningen, The Netherlands
p.e.de.jong@int.azg.nl

Kunihiro Matsushita, MD, PhD
Johns Hopkins University
Baltimore, USA
kmatsush@jhsph.edu

Marije van der Vilde
University Hospital Groningen
Groningen, The Netherlands
m.van.der.velde@int.umcg.nl
CONFERENCE ATTENDEES:

Dennis Andress, MD  
Invited Observer  
Abbott Labs  
Abbott Park, IL USA  
dennis.andress@abbott.com

Johannes Ärnlöv, MD, PhD  
Uppsala University  
Uppsala, Sweden  
Uppsala Longitudinal Study of Adult Men (ULSAM) Study  
johan.arnlov@pubcare.uu.se

Brad Astor, PhD  
Johns Hopkins University  
Baltimore, USA  
Third National Health and Nutrition Examinations Survey (NHANES III)  
bastor@jhsph.edu

Robert Atkins, MD  
Monash Medical Centre  
Clayton VIC, Australia  
Australian Diabetes, Obesity and Lifestyle (AusDiab I & II) Study  
Bob.Atkins@med.monash.edu.au

Brendan Barrett, MD  
Patient Research Center, St. John's  
St. John's, NL, Canada  
Canadian Prevention of Renal and Vascular Endpoints Trial (Can-Prevent)  
bbarrett@mun.ca

Shaila Basavappa, MSc, Dphil  
Invited Observer  
Takeda Pharmaceuticals  
Deerfield, IL, USA  
sbasavappa@takedaglobal.com

Jeffrey Berns, MD, FACP, FACN  
University of Pennsylvania  
Philadelphia, USA  
jeffrey.berns@uphs.upenn.edu

Henk Bilo, MD, PhD, FRCP  
Isala Clinics  
Zwolle, The Netherlands  
Zwolle Outpatient Diabetes project Involving Available Care (ZODIAC)  
h.j.g.bilo@isala.nl

Eric Cantor, MD  
Invited Observer  
GE Healthcare, Medical Diagnostics  
New York, USA  
Eric.Cantor@ge.com

Massimo Cirillo, MD  
Second University of Naples  
Naples, Italy  
Gubbio Population Study  
massimo.cirillo@unina2.it

Alan Collins, MD  
University of Minnesota  
Minneapolis, USA  
Kidney Early Evaluation Program (KEEP)  
acollins@nephrology.org

Brian Copley, MD  
Invited Observer  
Bristol-Myers Squibb  
Villanova, PA, USA  
brian.copley@bms.com

Josef Coresh, MD, PhD  
Johns Hopkins University  
Baltimore, USA  
Atherosclerosis Risk in Communities (ARIC)  
coresh@jhu.edu

Paul de Jong, MD, PhD  
University Hospital Groningen  
Groningen, The Netherlands  
p.e.de.jong@int.azg.nl
Kunitoshi Iseki, MD  
University Hospital of the Ryukyus  
Nishihara, Japan  
Okinawa General Health Maintenance  
Association (OGHMA) and Okinawa  
Dialysis Study (OKIDS) registry  
chihokun@med.u-ryukyu.ac.jp

Areef Ishani, MD, MS  
University of Minnesota, Minneapolis VA  
Medical Center  
Minneapolis, USA  
Multiple Risk Factor Intervention Trial (MRFIT)  
areef.ishani@va.gov

Tazeen Jafar, MD, MPH  
Aga Khan University  
Karachi, Pakistan  
Control of Blood Pressure and Risk  
Attenuation  
Tazeen.jafar@aku.edu

Simerjot Jassal, MD  
University of California-San Diego  
San Diego, USA  
Rancho Bernardo Study  
sjassal@ucsd.edu

Sun Ha Jee, PhD, MPH  
Yonsei University  
Seoul, Korea  
Severance Cohort Study  
jsunha@yuhs.ac

Hanneke Joosten, MD  
University Medical Centre Groningen  
Zwolle, The Netherlands  
ZODIAC: Zwolle Outpatient Diabetes project Involving Available Care  
j.m.h.joosten@isala.nl

Andrzej Krolewski, MD, PhD  
Joslin Diabetes Center  
Boston, USA  
Predictors of End Stage Renal Disease in Patients with Type 1 Diabetes and Proteinuria  
andrzej.krolewski@joslin.harvard.edu

Florian Kronenberg, MD  
University of Innsbruck Medical School  
Innsbruck, Austria  
Mild to Moderate Kidney Disease (MMKD) Study  
Florian.Kronenberg@i-med.ac.at

Norbert Lameire, MD  
Ghent University Hospital  
Ghent, Belgium  
norbert.lameire@ugent.be

Martin Landray, PhD, MRCP  
University of Oxford  
Oxford, UK  
Chronic Renal Impairment in Birmingham (CRIB) Study  
martin.landray@ctsu.ox.ac.uk

Brian Lee, MD  
Kaiser Permanente Clinic  
Honolulu, USA  
Kaiser Permanente - Hawaiian Cohort  
Brian.J.Lee@kp.org

Adeera Levin, MD  
St. Paul's Hospital  
Vancouver, Canada  
British Columbia CKD Provincial Database and Canadian Care Prior to Dialysis (CAN-CARE)  
KDIGO Executive Committee  
alevin@providencehealth.bc.ca
Annalisa Perna, Stat.Sci.D
Mario Negri Institute for Pharmacological Research
Bergamo, Italy
Ramipril Efficacy In Nephropathy (REIN and REIN2)
Annalisa.Perna@marionegri.it

Kevan Polkinghorne, MBChB, MClinEpi, FRACP, PhD
Monash Medical Centre & Monash University
Melbourne, Australia
Australian Diabetes, Obesity and Lifestyle (AusDiab I & II) Study
kevan.polkinghorne@med.monash.edu.au

Mahboob Rahman, MD
Cleveland Clinic
Cleveland, USA
Chronic Renal Insufficiency Cohort (CRIC) Study
Mahboob.Rahman@UHhospitals.org

Miguel Riella, MD, PhD
Catholic University of Parana
Curitiba, Brazil
KDIGO Executive Committee
mcriella@pro-renal.org.br

Michael Rocco, MD, MSCE
Wake Forest University
Winston Salem, USA
mrocco@wfubmc.edu

Paul Roderick, MD
University of Southampton
Southampton, UK
Chronic kidney disease and mortality risk in older people: a community-based population study in the United Kingdom
pjr@soton.ac.uk

Peter Rossing, MD, DMSc
Steno Diabetes Center
Gentofte, Denmark
STENO Diabetes Center Study
pro@steno.dk

Dietrich Rothenbacher, MD, MPH
Universitäts Klinikum Heidelberg
Heidelberg, Germany
ESTHER-study (Germany)
d.rothenbacher@dkfz-heidelberg.de

Mark Sarnak, MD, MS
Tufts Medical Center
Boston, USA
Modification of Diet in Renal Disease (MDRD) Study
msarnak@tuftsmedicalcenter.org

Robert Schrier, MD
University of Colorado Health Services Center
Denver, USA
KDIGO Executive Committee
robert.schrier@uchsc.edu

Anoop Shankar, MD, PhD
Center for Interdisciplinary Research in Cardiovascular Sciences
Morgantown, USA
Beaver Dam Chronic Kidney Disease Study
ashankar@hsc.wvu.edu

Michael Shlipak, MD, MPH
Invited Speaker
Veteran's Affairs Medical Center
San Francisco, USA
Multi-Ethnic Study of Atherosclerosis (MESA) & Cardiovascular health Study
michael.shlipak@ucsf.edu
David Smith, RPh, MHA, PhD  
Kaiser Permanente Center for Health Research  
Portland, USA  
Kaiser Pacific Northwest: Developing a Risk Equation to Predict Mortality and Progression to End Stage Renal Disease  
david.h.smith@kpchr.org

Benedicte Stengel, MD, PhD  
INSERM  
Villejuif, France  
NephroTest  
benedicte.stengel@inserm.fr

Lesley Stevens, MD, MS  
Invited Speaker  
Tufts Medical Center  
Boston, USA  
lstevens1@tuftsmedicalcenter.org

Paul Stevens, MBBS, BSc, FRCP  
Kent and Canterbury Hospital  
Canterbury, UK  
Paul.Stevens@ekht.nhs.uk

Nihad A.M. Tamimi, MD  
Invited Observer  
Pfizer Global Research & Development  
Canterbury, United Kingdom  
Nihad.tamimi@pfizer.com

Marcello Tonelli, MD  
University of Alberta  
Edmonton, Canada  
Cholesterol and Recurrent Events Study (CARE)  
mtonelli@ualberta.ca

Yusuke Tsukamoto, MD  
Shuwa General Hospital  
Tokyo, Japan  
KDIGO Executive Committee  
tsukamoto@jinzou.net

Katrin Uhlig, MD, MS  
Tufts Medical Center  
Boston, USA  
kuhlig@tuftsmedicalcenter.org

Anil Upadhyay, MD  
Invited Observer  
Mitsubishi Pharma Europe Ltd  
London, UK  
AUpadhyay@m-pharma.co.uk

Raymond Vanholder, MD, PhD  
University Hospital Ghent  
Ghent, Belgium  
KDIGO Executive Committee  
Raymond.Vanholder@ugent.be

Joseph Vassalotti, MD  
National Kidney Foundation  
New York, USA  
JoeV@kidney.org

Fang Wang, MD  
Peking University  
Beijing, China  
Beijing Cohort: 5 years follow-up for the population survey of citizens older than 40  
wangfang@bjmu.edu.cn

HaiYan Wang, MD  
Peking University  
Beijing, China  
Beijing Cohort: 5 years follow-up for the population survey of citizens older than 40  
why@bjmu.edu.cn

David Warnock, MD  
University of Alabama at Birmingham  
Birmingham, USA  
Renal - REasons for Geographic And Racial Differences in Stroke (REGARDS) Study  
dwarnock@uab.edu
Chi-Pang Wen, MD, MPH, DrPH  
University of Wisconsin  
Madison, USA  
Taiwan Cohort  
cwengood@nhri.org.tw

Sung-Feng Wen, MD  
University of Wisconsin  
Madison, USA  
Taiwan Cohort  
sfw@medicine.wisc.edu

Jessica Robin Weinstein, MD  
Oregon Health and Sciences University  
Portland, USA  
Kaiser Pacific Northwest: Developing a Risk Equation to Predict Mortality and Progression to End Stage Renal Disease  
Jessica.R.Weinstein@kpchr.org

Jack Wetzels, MD, PhD  
Radboud University Nijmegen Medical Center  
Nijmegen, The Netherlands  
MASTERPLAN  
j.wetzels@nier.umcn.nl

David Wheeler, MD, FRCP  
Royal Free and University College Medical School  
London, UK  
Chronic Renal Impairment in Birmingham (CRIB) Study  
KDIGO Executive Committee  
d.wheeler@medsch.ucl.ac.uk

Desmond Williams, MD, PhD  
Centers for Disease Control and Prevention  
Atlanta, USA  
DEWilliams@cdc.gov

Dan Wilson, MD  
Invited Observer  
Pfizer Medical Director  
New York, USA  
DanielJ.Wilson@pfizer.com

Christopher Winearls, MB, FRCP, DPhil  
Oxford Kidney Unit, Oxford University  
Oxford, UK  
chris.winearls@orh.nhs.uk

Mark Woodward, MD  
Mt. Sinai School of Medicine  
New York, USA  
The Action in Diabetes and Vascular disease: preterAx and diamicron-MR Controlled Evaluation (ADVANCE) study  
Mark.Woodward@mountsinai.org

Jackson Wright, MD, PhD, FACP  
Case Western Reserve University  
Cleveland, USA  
African American Study of Kidney Disease and Hypertension (AASK) Cohort Study  
jxw20@case.edu